- Pacira Pharmaceuticals (PCRX) is out with results from Phase 4 studies of Exparel in laparoscopic colectomy patients.
- The company says the data "reinforce findings from [the] IMPROVE trials ... demonstrating the opioid-sparing and economic benefits of Exparel."
- Patients receiving the Exparel-based multimodal regimen experienced:"A 64 mg reduction in mean opioid consumption," "a 1-day reduction in median length of hospital stay," "significantly fewer opioid-related adverse events," and "a $1,784 reduction in mean hospitalization costs." (PR)
Pacira Pharmaceuticals, Inc. (PCRX): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report
at Zacks.com (Nov 3, 2014)